著者

鈴木 美佳

出版者

公益社団法人 日本地理学会

雑誌

地理学評論 Series A (ISSN:18834388)

巻号頁・発行日

vol.94, no.3, pp.152-169, 2021-05-01 (Released:2023-02-19)

参考文献数

16

被引用文献数

3

---

本稿では自転車の共同利用システムであるシェアサイクルについて,利用目的ごとの傾向と,現状における運営上の課題を明らかにすることを目的とする.三つの都市での事例から得た利用データの分析により,通勤・通学目的での利用が多い場合は駅を発着地とする移動が多く,観光目的での利用が多い場合は地域の観光拠点を結ぶ移動が多いことが判明した.一方,主な利用目的にかかわらず,駅周辺ポートの利用数が全体に占める割合は高くなっていた.各事例の運営主体への聞取り調査からは,先行研究で指摘されている通り自転車数やポート配置の調整によって利用率は高まるものの,利用料金が廉価なためシェアサイクル事業独立で採算をとることは難しいという現状が明らかになった.持続可能性を高めるためには,既存交通を結びつける移動手段として位置づけ,行政からの支援制度を整えること,自転車専用道の整備など他の交通施策も同時に行うことがのぞまれる.

著者

青木 良子 佐井 君江 勝田 由紀子 鈴木 美佳 鈴木 康夫 石井 明子 斎藤 嘉朗

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.142, no.5, pp.547-560, 2022-05-01 (Released:2022-05-01)

参考文献数

19

被引用文献数

1

---

Biosimilars are less expensive than their originators, and Japanese government policies call for their development and promotion. However, the adoption and prescription of some biosimilars, especially antibody/its-related ones, have been delayed for use in Japan, possibly due to concerns on the differences in quality attributes such as glycan structures between the originators and their biosimilars, and that clinical efficacy/safety studies are conducted for usually one disease and its results extrapolated to other indications. We conducted a questionnaire survey among physicians in four disease areas (hematology, medical oncology, rheumatoid arthritis, and inflammatory bowel disease), where biosimilars of antibody/its-related drugs have been approved, regarding their thoughts on the adoption and prescription of biosimilars in Japan from January to April 2020. We received totally 1024 responses. When adopting biosimilars and explaining them to patients, physicians requested specific information including the comparative results of phase III clinical trials and quality characteristics between biosimilars and their originators; the results of clinical studies on switching from originators to their biosimilars; and a comparison of the estimated cost on patients in consideration of the high medical cost payment system. Priority differed depending on the studied disease areas. In terms of post-marketing information, physicians requested a variety of information. When explaining biosimilars to the patients, physicians would like to use general material from government describing the comparability between originators and their biosimilars. These results suggest that physicians sought more comparative information on the quality, efficacy, and patients' cost between originators and their biosimilars when adopting or prescribing biosimilars.